Moscow, January 18 2013 – Janssen announced today during the Gaidar Forum, an annual economic and political gathering, the signing of two licensing agreements for drug development and commercialisation in the areas of oncology and tuberculosis with NewVac LLC, a ChemRar company, and Pharmstandard JSC, respectively.
Janssen is one of the top ten pharmaceutical companies in the Russian market, contributing to the expansion of the health care system and increasing its efforts in local research & development activities.
Read the press release about the new agreements.